DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

BIIB·Biogen Inc.

$.
-. (-.%)
After Hours
High
$195.79
Open
$194.39
Market Cap
28.51B
52W High
$205.97
Low
$192.27
P. Close
$193.10
P/E
20.78
52W Low
$121.05
Fwd P/E
11.64
Mean Target
$219.27
Technical Score (1D)
68
BUY
News Sentiment
46
MIXED
Ionis Pharmaceuticals is anticipating a significant year with multiple regulatory decisions and clinical readouts. A key event to watch is the PDUFA decision for TRYNGELZA, expected on June 30, for severe hypertriglyceridemia. Ionis has raised its peak sales outlook for TRYNGELZA to over $3 billion, supported by strong clinical data and favorable pricing research. Additionally, positive Biogen tau data in Alzheimer's disease was noted, which could potentially advance to Phase 3. This Alzheimer's development is particularly relevant as it suggests continued progress in a critical therapeutic area for Biogen. Investors will be monitoring the outcome of the TRYNGELZA decision closely as it represents a near-term catalyst. Further updates on the Biogen tau data progression will also be important for assessing long-term pipeline potential.
Earnings Summary
Biogen Inc. is a global biotechnology company dedicated to discovering and delivering therapies for neurological and neurodegenerative diseases, focusing on conditions such as multiple sclerosis and spinal muscular atrophy. Operating within the drug manufacturers general industry, Biogen's pipeline and existing treatments address significant unmet medical needs in neuroscience. In its most recent reported quarters, Biogen experienced a significant divergence in performance. For Q1 2026, the company reported actual EPS of $3.57 against an estimate of $2.95216, with actual revenue at $2.4778 billion against an estimate of $2.24747 billion. This followed Q4 2025, where actual EPS was $1.99 compared to an estimate of $1.626, with actual revenue at $2.2794 billion against an estimate of $2.24801 billion. Prior to this, Q3 2025 saw actual EPS of $4.81 against an estimate of $3.88288, and Q2 2025 reported a substantial actual EPS of $5.47 against an estimate of $3.88017. Biogen has demonstrated a strong pattern of beating EPS estimates in the last four reported quarters, with particularly large beats in Q2 and Q3 2025. Revenue performance has also been strong, beating estimates in Q1 2026 and Q4 2025, and showing significant growth in Q2 2025. Historically, Biogen's year-over-year growth trajectory has been influenced by its pipeline developments and product cycles. The company has a track record of significant beats against analyst expectations, especially in recent periods, indicating strong operational execution or favorable market conditions for its products. Recent news indicates significant challenges, including a securities fraud investigation following the failure of its Alzheimer's therapy diranersen in a Phase 2 trial, and the discontinuation of Parkinson's candidate BIIB122 due to failed Phase 2b trials. These setbacks have led to a notable share price drop and increased scrutiny. Moving forward, investors will be closely watching for updates on the securities fraud investigation and the company's strategic response to these pipeline challenges. Key will be Biogen's ability to navigate these setbacks and demonstrate progress in its remaining pipeline assets.

EPS

EstBeatMiss
$1.05$2.30$3.55$4.80$6.05Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.94 - -
Q1'26$2.95$3.57+20.9%
Q4'25$1.63$1.99+22.4%
Q3'25$3.88$4.81+23.9%
Q2'25$3.88$5.47+41.0%
Q1'25$2.95$3.02+2.4%

Revenue

EstBeatMiss
$2.2B$2.3B$2.4B$2.6B$2.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.5B - -
Q1'26$2.2B$2.5B+10.2%
Q4'25$2.2B$2.3B+1.4%
Q3'25 - $2.5B -
Q2'25 - $2.6B -
Q1'25 - $2.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BIIB Stock Snapshot

BIIB is currently trading at $193.08, giving Biogen Inc. a market cap of 28.51B and a P/E ratio of 20.8. Today's range spans $192.27–$195.79, with shares opening at $194.39 and moving down $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 46/100.

Over the past year BIIB has traded between $121.05 and $205.97 - the current price is +59.5% off the 52-week low and -6.3% from the high. 44 analysts cover the stock with a Hold consensus and a mean 12-month target of $219.27 (range $150.00–$300.00), implying upside of +13.6%.

Dividend-paying Healthcare stocks at the large-cap level tend to attract a different buyer mix than pure growth names - and BIIB (28.51B market cap) with a BUY read (68/100) and neutral sentiment (46/100) benefits from both income-oriented and growth-oriented flows. The current P/E ratio stands at 20.8. Price: $193.08 (in the upper portion of its 52-week range in $121.05–$205.97). When technical momentum aligns with that dual-buyer base, the price path tends to be more durable than single-buyer-type momentum trades.

The combination of a BUY signal (68/100) and neutral news sentiment (46/100) puts BIIB on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 28.51B in Healthcare market cap without immediately moving the stock. At $193.08 (in the upper portion of its 52-week range in the $121.05–$205.97 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.